11:43 AM EST - Medicago Inc. : reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate. The vaccine was found to be safe, well tolerated and also induced a solid immune response. Medicago Inc.
shares V.MDG are trading down $0.04 at $0.57.
